via University of Illinois Chicago
A new compound developed at the University of Illinois Chicago potentially could offer an alternative to injections for the millions of people who suffer from an eye condition that causes blindness.
Wet age-related macular degeneration causes vision loss due to the uncontrolled growth and leakage of blood vessels in the back of the eye. A new paper in Cell Reports Medicine led by UIC researcher Yulia Komarova finds that a small-molecule inhibitor can reverse damage from AMD and promote regenerative and healing processes.
The drug can also be delivered via eyedrops — an improvement over current treatments for AMD, which require repeated injections into the eye.
“The idea was to develop something that can be more patient-friendly and doesn’t require a visit to the doctor’s office,” said Komarova, associate professor of pharmacology at the College of Medicine.
Komarova’s compound targets a protein called End Binding-3 in endothelial cells, which line the inside of blood vessels. In the new study, the researchers looked at whether inhibiting EB3 function could stop the damaging leakage associated with wet AMD.
Using computational drug design methods, the team developed a small inhibitor that could be delivered externally via eyedrops instead of by injection. They then tested its effectiveness in animal models of wet AMD, finding that twice-daily treatment reduced eye damage within 2 to 3 weeks.
Further investigation found that the inhibitor worked by rolling back aging-related genetic modifications. Aging causes inflammation and hypoxia in the eye that leads to changes in gene expression associated with the cellular effects and symptoms of wet AMD. Komarova and colleagues found that the EB3 inhibitor they developed reversed these epigenetic changes, restoring gene expression to a normal, healthy state.
“We reduce the effects of the stressor on endothelial cells and we improve regenerative processes, accelerating healing,” Komarova said. “That can be tremendous for the function of the cells.”
Because blood vessel leakage and hypoxic stress also drive many other medical conditions, Komarova’s group is interested in testing the inhibitor in models of acute lung injury, diabetic retinopathy, stroke, heart disease and even the general effects of aging on the brain. They’re also exploring whether an implantable lens, similar to a contact lens, could deliver the drug to the eye more effectively than eyedrops.
Original Article: New strategy for eye condition could replace injections with eyedrops
More from: University of Illinois at Chicago | University of Illinois College of Medicine
The Latest Updates from Bing News
Go deeper with Bing News on:
Age-related macular degeneration
- Nanoscope Therapeutics Appoints New Chief Medical Officer
Dallas-based Nanoscope said Dr. Allen C. Ho will help define the strategy of developing its gene mutation-agnostic therapies. Ho is attending surgeon and director of retina research at Wills Eye ...
- CIRM awards $31 million to fund clinical-stage research for cancers and eye disease
South San Francisco, CA, April 26, 2024 – The California Institute for Regenerative Medicine (CIRM), one of the world’s largest institutions dedicated to regenerative medicine, has approved awarding ...
- Science Corporation acquires retinal implant from Pixium Vision
S cience Corporation, a brain-computer interface technology company, has announced the acquisition of intellectual property and related assets for the Prima retinal implant from French bioelectronics ...
- Local group helps macular degeneration patients cope with vision loss
To provide opportunity for encouragement, Phoenix-based Associated Retina Consultants, in coordination with the International Low Vision Support Group, has established a Macular Degeneration Support ...
- BCI maker Science acquires retinal implant from Pixium Vision
Brain-computer interface developer Science Corporation acquired the IP and related assets for the Pixium Vision Prima implant.
Go deeper with Bing News on:
Wet age-related macular degeneration,
- Local group helps macular degeneration patients cope with vision loss
To provide opportunity for encouragement, Phoenix-based Associated Retina Consultants, in coordination with the International Low Vision Support Group, has established a Macular Degeneration Support ...
- Dr. Roach: Eye drops safe to use with AMD medication
Dear C.H.: Eylea is used to treat several cancers as well as the “wet” form of AMD. Eylea works by preventing the formation of new blood vessels and blocking a compound called the vascular endothelial ...
- Dry Age-related Macular Degeneration Seven Major Market to Exhibit Growth at a CAGR of 19.8% by 2034 | DelveInsight
DelveInsight's Dry Age-related Macular Degeneration Market Insights report includes a comprehensive understanding of current treatment practices, dry age-related macular degeneration marketed drug, ...
- Wet vs. Dry Macular Degeneration: What Is the Difference?
Both types of age-related macular degeneration (AMD) can cause blurriness and visual changes. Dry AMD progresses slowly and causes permanent damage, while wet AMD is more severe but more treatable.
- Items Tagged with 'wet age-related macular degeneration'
With credit card fees taking a sizable bite of their billings, many U.S. health care providers are fighting back by offering patients cash discounts. But when a drug company covers card processing ...